Maria Cristina Manara

List of Publications by Year
in descending order

103 papers	4,923 citations	76196 40 h-index	98622 67 g-index
103 all docs	103 docs citations	103 times ranked	5006 citing authors

#	Article	IF	Citations
1	Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma. Cancer Research, 2022, 82, 708-720.	0.4	16
2	Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma. Cell Death and Disease, 2022, 13, 346.	2.7	7
3	Novel Targeting of DNA Methyltransferase Activity Inhibits Ewing Sarcoma Cell Proliferation and Enhances Tumor Cell Sensitivity to DNA Damaging Drugs by Activating the DNA Damage Response. Frontiers in Endocrinology, 2022, 13, .	1.5	4
4	Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study. Cancers, 2022, 14, 2863.	1.7	6
5	Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma. Cells, 2021, 10, 416.	1.8	19
6	Impact of ABC Transporters in Osteosarcoma and Ewingâ€™s Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?. Cells, 2021, 10, 2461.	1.8	9
7	Ewing Sarcoma PDX Models. Methods in Molecular Biology, 2021, 2226, 223-242.	0.4	11
8	Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Modulates Aggressiveness of Ewing Sarcoma by Regulating the CD164-CXCR4 Axis. Frontiers in Oncology, 2020, 10, 994.	1.3	12
9	Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma. Journal of Cell Communication and Signaling, 2020, 14, 335-347.	1.8	8
10	Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. Scientific Reports, 2019, 9, 12174.	1.6	52
11	Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells. Clinical Epigenetics, 2019, 11, 68.	1.8	30
12	ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity. Journal of Experimental and Clinical Cancer Research, 2019, 38, 503.	3.5	36
13	Abstract 3672: Insulin-like growth factor 2 (IGF-2) mRNA binding protein 3-mediated regulation of CD164-CXCR4 axis impacts aggressiveness of Ewing sarcoma. , 2019, , .		0
14	Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99. Oncogene, 2018, 37, 2181-2196.	2.6	24
15	CD99 at the crossroads of physiology and pathology. Journal of Cell Communication and Signaling, 2018, 12, 55-68.	1.8	101
16	Oxidative Stress in Autistic Children Alters Erythrocyte Shape in the Absence of Quantitative Protein Alterations and of Loss of Membrane Phospholipid Asymmetry. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-11.	1.9	20
17	A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy. Molecular Cancer Therapeutics, 2018, 17, 1881-1892.	1.9	33
18	Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Influences Sensitivity to Anti-IGF System Agents Through the Translational Regulation of IGF1R. Frontiers in Endocrinology, 2018, 9, 178.	1.5	37

#	Article	IF	Citations
19	CD99: A Cell Surface Protein with an Oncojanus Role in Tumors. Genes, 2018, 9, 159.	1.0	60
20	Abstract 2079: Collection of patient-derived xenografts (PDX) to study the biology and therapy of bone sarcomas. , 2018, , .		0
21	Abstract A06: Inhibition of CD99 activity by clofarabine as a novel therapeutic for Ewing sarcoma involves a novel molecular mechanism that is different than cytarabine. , 2018, , .		0
22	Targeting ROCK2 rather than ROCK1 inhibits Ewing sarcoma malignancy. Oncology Reports, 2017, 37, 1387-1393.	1.2	12
23	Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2017, 23, 5149-5161.	3.2	59
24	Abstract 1933: Discovery of first-in-class small molecule CD99 inhibitors for targeted therapy of Ewing sarcoma. , 2017, , .		1
25	Does MGMT (O6-methylguanineâ€“DNA methyltransferase) have a role in metastatic Ewing sarcoma (ES) patients (pts) undergoing temozolomide (TMZ) and irinotecan (IRI)?. Journal of Clinical Oncology, 2017, 35, 11030-11030.	0.8	0
26	Process development of a human recombinant diabody expressed in E. coli: engagement of CD99-induced apoptosis for target therapy in Ewingâ€™s sarcoma. Applied Microbiology and Biotechnology, 2016, 100, 3949-3963.	1.7	6
27	CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-ÎºB signaling. Oncogene, 2016, 35, 3944-3954.	2.6	51
28	CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling. Oncotarget, 2016, 7, 79925-79942.	0.8	40
29	Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents. Clinical Cancer Research, 2015, 21, 1373-1382.	3.2	39
30	CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin. Clinical Cancer Research, 2015, 21, 146-156.	3.2	42
31	ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents. Oncotarget, 2015, 6, 16611-16622.	0.8	18
32	Abstract 2946: Effects of two novel quinoline-based non-nucleoside DNA methyltransferase inhibitors against bone sarcomas. , 2015, , .		0
33	Characterization of Human Mesenchymal Stem Cells from Ewing Sarcoma Patients. Pathogenetic Implications. PLoS ONE, 2014, 9, e85814.	1.1	38
34	Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression. Annals of Oncology, 2014, 25, 2080-2086.	0.6	35
35	CD99 Drives Terminal Differentiation of Osteosarcoma Cells by Acting as a Spatial Regulator of ERK 1/2. Journal of Bone and Mineral Research, 2014, 29, 1295-1309.	3.1	37
36	CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. Oncogene, 2014, 33, 1912-1921.	2.6	41

#	Article	IF	Citations
37	Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells. Growth Factors, 2014, 32, 41-52.	0.5	18
38	An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. BMC Cancer, 2014, 14, 137.	1.1	13
39	miRNA expression profile in human osteosarcoma: Role of miR-1 and miR-133b in proliferation and cell cycle control. International Journal of Oncology, 2013, 42, 667-675.	1.4	106
40	Metformin as an Adjuvant Drug against Pediatric Sarcomas: Hypoxia Limits Therapeutic Effects of the Drug. PLoS ONE, 2013, 8, e83832.	1.1	43
41	Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis. Current Pharmaceutical Design, 2013, 19, 5344-5361.	0.9	8
42	Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewingâ€™s Sarcoma Tumor Cells. Current Pharmaceutical Biotechnology, 2013, 14, 449-463.	0.9	18
43	Identification of Common and Distinctive Mechanisms of Resistance to Different Anti-IGF-IR Agents in Ewing's Sarcoma. Molecular Endocrinology, 2012, 26, 1603-1616.	3.7	53
44	miRâ€34a predicts survival of Ewing's sarcoma patients and directly influences cell chemoâ€sensitivity and malignancy. Journal of Pathology, 2012, 226, 796-805.	2.1	128
45	Abstract 4140: MicroRNA expression in Osteosarcoma: potential role of miR-1 and miR-133b. , 2012, , .		0
46	Abstract 4325: CD99 suppresses osteosarcoma cell migration by favouring the oncosoppressor N-cadherin/beta-catenin signalling pathway in contrast to ezrin.. , 2012, , .		0
47	Expression of insulin-like growth factor system components in Ewingâ€™s sarcoma and their association with survival. European Journal of Cancer, 2011, 47, 1258-1266.	1.3	49
48	Targeting Glutathione-S Transferase Enzymes in Musculoskeletal Sarcomas: A Promising Therapeutic Strategy. Analytical Cellular Pathology, 2011, 34, 131-145.	0.7	20
49	Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene, 2011, 30, 2730-2740.	2.6	119
50	Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. Analytical Cellular Pathology, 2011, 34, 131-45.	0.7	17
51	Abstract 728: Molecular mechanisms of resistance to anti-IGF-1R therapies in Ewing's sarcoma. , 2011, , .		0
52	Abstract 167: Identification of miR-34a as a prognostic biomarker of Ewing sarcoma family of tumors. , 2011, , .		0
53	Abstract 5340: Regulation of osteoblast differentiation: The pivotal role of CD99 molecule. , 2011, , .		0
54	Biological indicators of prognosis in Ewing's sarcoma: An emerging role for lectin galactosideâ€binding soluble 3 binding protein (LGALS3BP). International Journal of Cancer, 2010, 126, 41-52.	2.3	31

#	Article	IF	Citations
55	Xg Expression in Ewing's Sarcoma Is of Prognostic Value and Contributes to Tumor Invasiveness. Cancer Research, 2010, 70, 3730-3738.	0.4	21
56	NVP-BEZ235 as a New Therapeutic Option for Sarcomas. Clinical Cancer Research, 2010, 16, 530-540.	3.2	142
57	CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. Journal of Clinical Investigation, 2010, 120, 668-680.	3.9	150
58	Abstract 3406: Prognostic relevance of Wnt-beta catenin signaling in Ewing's sarcoma. , 2010, , .		0
59	Overcoming Resistance to Conventional Drugs in Ewing Sarcoma and Identification of Molecular Predictors of Outcome. Journal of Clinical Oncology, 2009, 27, 2209-2216.	0.8	121
60	Insulinâ€like growth factor 1 receptor expression in wildâ€type GISTs: A potential novel therapeutic target. International Journal of Cancer, 2009, 125, 2991-2994.	2.3	70
61	Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. Annals of Oncology, 2008, 19, 1500-1508.	0.6	48
62	Caveolin-1 Reduces Osteosarcoma Metastases by Inhibiting c-Src Activity and Met Signaling. Cancer Research, 2007, 67, 7675-7685.	0.4	81
63	Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor-Specific Inhibitor in Ewing's Sarcoma. Clinical Cancer Research, 2007, 13, 1322-1330.	3.2	126
64	Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Letters, 2007, 250, 194-205.	3.2	43
65	CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. Oncogene, 2007, 26, 6604-6618.	2.6	59
66	Domain-specific CCN3 antibodies as unique tools for structural and functional studies. Journal of Cell Communication and Signaling, 2007, 1, 91-102.	1.8	24
67	Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewingâ€™s sarcoma. European Journal of Cancer, 2006, 42, 91-96.	1.3	69
68	RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells. British Journal of Cancer, 2006, 94, 1300-1310.	2.9	26
69	Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. International Journal of Cancer, 2006, 119, 1039-1046.	2.3	49
70	CD99 Acts as an Oncosuppressor in Osteosarcoma. Molecular Biology of the Cell, 2006, 17, 1910-1921.	0.9	60
71	May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. International Journal of Oncology, 2006, 29, 1459-68.	1.4	20
72	In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene, 2005, 24, 4349-4361.	2.6	90

#	Article	IF	Citations
73	Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors. Cancer Research, 2005, 65, 3868-3876.	0.4	272
74	Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewingâ€™s sarcoma. European Journal of Cancer, 2005, 41, 1349-1361.	1.3	123
75	4-Demethoxy-3â€²-deamino-3â€²-aziridinyl-4â€²-methylsulphonyl-daunorubicin (PNU-159548): A promising new candidate for chemotherapeutic treatment of osteosarcoma patients. European Journal of Cancer, 2005, 41, 2184-2195.	1.3	9
76	Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Annals of Oncology, 2004, 15, 151-160.	0.6	83
77	Molecular mechanisms of CD99-induced caspase-independent cell death and cellâ€“cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene, 2004, 23, 5664-5674.	2.6	108
78	Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects. International Journal of Cancer, 2004, 108, 358-366.	2.3	61
79	Identification of candidate genes involved in the reversal of malignant phenotype of osteosarcoma cells transfected with the liver/bone/kidney alkaline phosphatase gene. Bone, 2004, 34, 672-679.	1.4	33
80	Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. European Journal of Cell Biology, 2003, 82, 483-493.	1.6	36
81	Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB Journal, 2003, 17, 1162-1164.	0.2	72
82	c-kit Receptor Expression in Ewingâ€™s Sarcoma: Lack of Prognostic Value but Therapeutic Targeting Opportunities in Appropriate Conditions. Journal of Clinical Oncology, 2003, 21, 1952-1960.	0.8	71
83	Value of P-Glycoprotein and Clinicopathologic Factors as the Basis for New Treatment Strategies in High-Grade Osteosarcoma of the Extremities. Journal of Clinical Oncology, 2003, 21, 536-542.	0.8	95
84	Impact of IGF-I/IGF-IR Circuit on the Angiogenetic Properties of Ewingâ€™s Sarcoma Cells. Hormone and Metabolic Research, 2003, 35, 675-684.	0.7	53
85	The Expression of ccn3(nov) Gene in Musculoskeletal Tumors. American Journal of Pathology, 2002, 160, 849-859.	1.9	99
86	Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. International Journal of Cancer, 2002, 101, 11-16.	2.3	96
87	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Therapy, 2002, 9, 296-307.	2.2	101
88	Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clinical Cancer Research, 2002, 8, 3893-903.	3.2	39
89	Simultaneous Paired Analysis of Numerical Chromosomal Aberrations and DNA Content in Osteosarcoma. Modern Pathology, 2001, 14, 710-716.	2.9	11
90	Prognostic Significance of Nuclear Accumulation of c-myc and mdm2 Proteins in Synovial Sarcoma of the Extremities. Oncology, 2000, 58, 253-260.	0.9	15

#	Article	IF	Citations
91	Identification of EWS/FLI-1 transcripts in giant-cell tumor of bone. International Journal of Cancer, 2000, 87, 328-335.	2.3	21
92	Murine model for skeletal metastases of Ewing's sarcoma. Journal of Orthopaedic Research, 2000, 18, 959-966.	1.2	22
93	Reversal of malignant phenotype in human osteosarcoma cells transduced with the alkaline phosphatase gene. Bone, 2000, 26, 215-220.	1.4	35
94	The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene, 1999, 18, 739-746.	2.6	35
95	Redundancy of autocrine loops in human osteosarcoma cells. , 1999, 80, 581-588.		78
96	Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor. Human Pathology, 1996, 27, 408-416.	1.1	94
97	Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities. Cytotechnology, 1996, 19, 253-256.	0.7	6
98	Clinical relevance of Ki-67 expression in bone tumors. Cancer, 1995, 75, 806-814.	2.0	90
99	Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome. New England Journal of Medicine, 1995, 333, 1380-1385.	13.9	372
100	Analysis of P-glycoprotein expression in osteosarcoma. European Journal of Cancer, 1995, 31, 1998-2002.	1.3	38
101	Pre-Treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin. International Journal of Cancer, 1994, 58, 95-101.	2.3	15
102	Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma. Journal of Cancer Research and Clinical Oncology, 1992, 119, 121-126.	1.2	13
103	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. , 0, .		1